Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Here's Why Investors Should Buy Masimo (MASI) Stock Now

By Zacks Investment ResearchStock MarketsMar 23, 2020 09:51PM ET
www.investing.com/analysis/heres-why-investors-should-buy-masimo-masi-stock-now-200518574
Here's Why Investors Should Buy Masimo (MASI) Stock Now
By Zacks Investment Research   |  Mar 23, 2020 09:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
+0.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MSFT
+0.46%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SYK
+0.37%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ARAY
+1.49%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MASI
+12.35%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
COO
+0.81%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Masimo Corporation (NASDAQ:MASI) is likely to gain from a plethora of developments and an impressive view for 2020.
Over the past year, the stock has rallied 10.3% against the industry’s 24.9% decline. Meanwhile, the S&P 500 index has slipped 18.2%.
This $8.27-billion medical technology company currently has a Zacks Rank #2 (Buy). Masimo’s earnings are expected to grow 23% in the next five years. Also, the company has a trailing four-quarter positive earnings surprise of 5.3%, on average.
Let’s take a closer look at the factors that are working in favor of the company right now.
Positive Developments
Masimo has seen a plethora of developments lately.
The company is providing discounts on its Rainbow platform to help customers manage blood supplies. This is likely to tackle the blood shortage due to the COVID-19 outbreak worldwide.
Also, the company recently acquired Germany’s TNI medical. Notably, TNI’s novel softFlow is expected to boost Masimo’s respiratory care product portfolio. The COVID-19 wave has ramped up the demand for TNI’s softFlow technology. Hence, this technology will provide Masimo with additional tools to address the growing number of people affected by pulmonary diseases.
Moreover, the company recently inked a deal with Imprivata concerning the integration of Imprivata Medical Device Access into Masimo’s Hospital Automation solutions that feature the Root Patient Monitoring and Connectivity Platform.
Further, Masimo has issued an impressive guidance for 2020.
The company expects 2020 product revenues of $1.04 billion, calling for growth of 12.3% year over year and11% at constant currency.
Adjusted earnings per share (EPS) are expected at $3.56.
Adjusted gross margin is projected at 68%, while adjusted operating margin is expected to be 24.7%.
Estimates Picture
For 2020, the Zacks Consensus Estimate for revenues is pegged at $1.04 billion, indicating an improvement of 10.4%. For adjusted EPS, the same stands at $3.56, suggesting growth of 10.6% from the year-ago quarter’s reported figure.
Other Key Picks
Other similar-ranked companies in the broader medical sector include Stryker Corporation (NYSE:SYK) , Accuray Incorporated (NASDAQ:ARAY) and The Cooper Companies (NYSE:COO) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth is expected at 10.1%.
Accuray’s fiscal fourth-quarter earnings are expected to skyrocket 150%.
IDEXX Laboratories’ first-quarter earnings growth is projected at 5.1%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time
See 8 breakthrough stocks now>>
IDEXX Laboratories’ first-quarter earnings growth is projected at 5.1%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Cooper Companies' long-term earnings growth is projected at 10.7%.Other similar-ranked companies in the broader medical sector include Stryker Corporation (SYK), Accuray Incorporated (ARAY) and The Cooper Companies (COO). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth is expected at 10.1%.
Accuray’s fiscal fourth-quarter earnings are expected to skyrocket 150%.
Cooper Companies' long-term earnings growth is projected at 10.7%.


Stryker Corporation (SYK): Free Stock Analysis Report

Accuray Incorporated (ARAY): Free Stock Analysis Report

Masimo Corporation (MASI): Free Stock Analysis Report

The Cooper Companies, Inc. (COO): Free Stock Analysis Report

Original post
Here's Why Investors Should Buy Masimo (MASI) Stock Now
 

Related Articles

Here's Why Investors Should Buy Masimo (MASI) Stock Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email